Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development...
48 KB (3,859 words) - 21:03, 17 August 2024
Biogen (UK) Ltd is a leading UK owner and operator of anaerobic digestion and composting plants based in Bedfordshire. It is responsible for the construction...
5 KB (499 words) - 14:02, 26 January 2024
people with Alzheimer's disease to reduce its buildup. It was developed by Biogen and Eisai. Aducanumab is given via intravenous infusion. Aducanumab was...
61 KB (4,888 words) - 07:49, 4 July 2024
esters, primarily dimethyl fumarate, and marketed as Fumaderm by Biogen Idec in Europe. Biogen would later go on to develop the main ester, dimethyl fumarate...
12 KB (963 words) - 16:09, 21 August 2024
funded by Cure SMA. Starting in 2012, Ionis partnered with Biogen on development and, in 2015, Biogen acquired an exclusive license to the drug for a US$75...
27 KB (2,095 words) - 07:27, 1 July 2024
James Mullen (CEO) (section Biogen)
as CEO between 2021 and 2022. He was formerly the president and CEO of Biogen Idec until he retired effective June 8, 2010. At the same time, he started...
5 KB (525 words) - 21:12, 27 January 2024
Biologics (50 per cent plus one share) and the U.S.-based Biogen Idec (50 per cent). In 2014, Biogen Idec agreed to commercialize future anti-TNF biosimilar...
140 KB (13,062 words) - 04:26, 26 August 2024
S2CID 46326042. "Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis" (Press release). Biogen Idec....
170 KB (18,095 words) - 13:49, 16 August 2024
merged with Biogen to form the third largest biotech firm in the United States. Rastetter was Executive Chair of the new company, Biogen IDEC, from 2003...
28 KB (2,562 words) - 23:59, 24 August 2024
application for accelerated approval for lecanemab. In September 2022, Biogen announced positive results from an ongoing phase III clinical trial. In...
27 KB (2,350 words) - 14:54, 23 August 2024